NCT06462014Completed
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data
Source: ClinicalTrials.gov · Last updated 11 Dec 2025
Brief summary (registry, in English)
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 507 (actual)
- First submitted
- 23 May 2024
- Start date
- 19 Jun 2024
- Primary completion date
- 13 Dec 2024
- Lead sponsor
- Pfizer
- Diseases
- Prostate cancer
- NCT number
- NCT06462014
What you commit to
- Study type: Observational
- Participants enrolled: 507
- From 19 Jun 2024 to the primary completion date, 13 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- had surgical castration (bilateral orchiectomy) any time before the index date
Who the study is looking for
- Male with ≥ 1 diagnosis for PC
- Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
- Index date: the initiation date of relugolix
- At least 18 years old at the index date
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.